• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥密克戎变异株的特性影响 COVID-19 大流行中公共卫生措施的效果。

Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic.

机构信息

Nagasaki University Graduate School of Biomedical Sciences, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan.

Medical Education Development Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

出版信息

Int J Environ Res Public Health. 2022 Apr 19;19(9):4930. doi: 10.3390/ijerph19094930.

DOI:10.3390/ijerph19094930
PMID:35564325
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9099739/
Abstract

Nonpharmaceutical and pharmaceutical public health interventions are important to mitigate the coronavirus disease 2019 (COVID-19) epidemic. However, it is still unclear how the effectiveness of these interventions changes with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) novel variants. This simulation study utilized data from Japan and investigated how the characteristic properties of the Omicron variant, which emerged in late 2021, influence the effectiveness of public health interventions, including vaccination, the reduction of interpersonal contact, and the early isolation of infectious people. Although the short generation time of the Omicron variant increases the effectiveness of vaccination and the reduction of interpersonal contact, it decreases the effectiveness of early isolation. The latter feature may make the containment of case clusters difficult. The increase of infected children during the Omicron-dominant epidemic diminishes the effects of previously adult-targeted interventions. These findings underscore the importance of monitoring viral evolution and consequent changes in epidemiological characteristics. An assessment and adaptation of public health measures against COVID-19 are required as SARS-CoV-2 novel variants continue to emerge.

摘要

非药物和药物公共卫生干预措施对于减轻 2019 年冠状病毒病(COVID-19)疫情非常重要。然而,对于这些干预措施的效果如何随着严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)新型变体的出现而变化,目前仍不清楚。本模拟研究利用来自日本的数据,研究了于 2021 年末出现的奥密克戎变体的特征属性如何影响公共卫生干预措施的效果,包括疫苗接种、减少人际接触和早期隔离感染人群。虽然奥密克戎变体的短代际时间增加了疫苗接种和减少人际接触的效果,但降低了早期隔离的效果。后者的特征可能使病例集群的控制变得困难。奥密克戎主导流行期间感染儿童的增加削弱了之前针对成年人的干预措施的效果。这些发现强调了监测病毒进化和随之而来的流行病学特征变化的重要性。随着 SARS-CoV-2 新型变体的不断出现,需要对 COVID-19 的公共卫生措施进行评估和调整。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/3ba186df22cb/ijerph-19-04930-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/ee6405bfdc7f/ijerph-19-04930-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/e26fa985d388/ijerph-19-04930-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/3ba186df22cb/ijerph-19-04930-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/ee6405bfdc7f/ijerph-19-04930-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/e26fa985d388/ijerph-19-04930-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e41b/9099739/3ba186df22cb/ijerph-19-04930-g003.jpg

相似文献

1
Properties of the Omicron Variant of SARS-CoV-2 Affect Public Health Measure Effectiveness in the COVID-19 Epidemic.奥密克戎变异株的特性影响 COVID-19 大流行中公共卫生措施的效果。
Int J Environ Res Public Health. 2022 Apr 19;19(9):4930. doi: 10.3390/ijerph19094930.
2
[Analyze the clinical characteristics of mild and severe SARS-CoV-2 infected patients based on the local Omicron variant epidemic].基于本地奥密克戎变异株流行情况分析新型冠状病毒感染轻症和重症患者的临床特征
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023 Jan;35(1):32-36. doi: 10.3760/cma.j.cn121430-20220406-00339.
3
Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.关注的紧急 SARS-CoV-2 变异株:用于快速检测和监测的新型多重实时 RT-PCR 检测方法。
Microbiol Spectr. 2022 Feb 23;10(1):e0251321. doi: 10.1128/spectrum.02513-21.
4
Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics.奥密克戎 SARS-CoV-2 新变体:全球流行情况以及生物学和临床特征。
Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. doi: 10.26355/eurrev_202112_27652.
5
Performance Evaluation of Five Rapid At-Home COVID-19 Antigen Tests against the Omicron Variant.五种快速家用 COVID-19 抗原检测试剂盒对奥密克戎变异株的性能评估
Microbiol Spectr. 2023 Feb 14;11(1):e0228622. doi: 10.1128/spectrum.02286-22. Epub 2022 Dec 15.
6
COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?COVID-19 疫苗接种和 SARS-CoV-2 奥密克戎(B.1.1.529)变异株:隧道尽头的曙光?
Int J Infect Dis. 2022 May;118:167-168. doi: 10.1016/j.ijid.2022.03.008. Epub 2022 Mar 9.
7
Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study.南非首次出现严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎(B.1.1.529)变异株疫情期间因新冠病毒病住院的儿童:一项多中心观察性研究
Lancet Child Adolesc Health. 2022 May;6(5):294-302. doi: 10.1016/S2352-4642(22)00027-X. Epub 2022 Feb 18.
8
SARS-CoV-2 B.1.1.529 (Omicron) Variant - United States, December 1-8, 2021.SARS-CoV-2 B.1.1.529(奥密克戎)变异株-美国,2021 年 12 月 1 日-8 日。
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734. doi: 10.15585/mmwr.mm7050e1.
9
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间,加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局,期间 B.1.617.2(德尔塔)和 B.1.1.529(奥密克戎)变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
10
Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 T-Cell Epitopes Identified in COVID-19 Convalescent Individuals.在 COVID-19 康复个体中鉴定的与 SARS-CoV-2 的奥密克戎变异株相关的突变和 CD8 T 细胞表位之间最小交叉。
mBio. 2022 Apr 26;13(2):e0361721. doi: 10.1128/mbio.03617-21. Epub 2022 Mar 1.

引用本文的文献

1
Molecular epidemiology of SARS-CoV-2 genome sentinel surveillance in commercial COVID-19 testing sites targeting asymptomatic individuals during Japan's seventh epidemic wave.日本第七波疫情期间,在针对无症状个体的商业 COVID-19 检测点进行的 SARS-CoV-2 基因组哨点监测的分子流行病学研究。
Sci Rep. 2024 Sep 9;14(1):20950. doi: 10.1038/s41598-024-71953-8.
2
What do we know about pathological mechanism and pattern of lung injury related to SARS-CoV-2 Omicron variant?我们对与 SARS-CoV-2 奥密克戎变异株相关的肺损伤的病理机制和模式了解多少?
Diagn Pathol. 2023 Feb 10;18(1):18. doi: 10.1186/s13000-023-01306-y.
3
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.

本文引用的文献

1
Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2-A Report From the US National COVID Cohort Collaborative.美国国家新冠队列协作组关于感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎(B.1.1.529)变异株儿童急性上呼吸道疾病的报告
JAMA Pediatr. 2022 Aug 1;176(8):819-821. doi: 10.1001/jamapediatrics.2022.1110.
2
COVID-19 Vaccine Provider Access and Vaccination Coverage Among Children Aged 5-11 Years - United States, November 2021-January 2022.COVID-19 疫苗接种服务可及性及 5-11 岁儿童疫苗接种覆盖率 - 美国,2021 年 11 月-2022 年 1 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):378-383. doi: 10.15585/mmwr.mm7110a4.
3
2020 年 2 月至 2022 年 3 月日本疫苗接种时代前后 SARS-CoV-2 抗体的年龄分层血清流行率。
Emerg Infect Dis. 2022 Nov;28(11):2198-2205. doi: 10.3201/eid2811.221127. Epub 2022 Oct 5.
4
Exploring spatiotemporal patterns of COVID-19 infection in Nagasaki Prefecture in Japan using prospective space-time scan statistics from April 2020 to April 2022.利用2020年4月至2022年4月的前瞻性时空扫描统计数据,探索日本长崎县新冠病毒感染的时空模式。
Arch Public Health. 2022 Jul 26;80(1):176. doi: 10.1186/s13690-022-00921-3.
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
Covid-19 疫苗对奥密克戎(B.1.1.529)变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
4
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.新冠病毒奥密克戎改变 TMPRSS2 的使用方式影响其感染性和融合性。
Nature. 2022 Mar;603(7902):706-714. doi: 10.1038/s41586-022-04474-x. Epub 2022 Feb 1.
5
The Burden of COVID-19 in Children and Its Prevention by Vaccination: A Joint Statement of the Israeli Pediatric Association and the Israeli Society for Pediatric Infectious Diseases.儿童COVID-19负担及其疫苗预防:以色列儿科学会和以色列儿科传染病学会联合声明
Vaccines (Basel). 2022 Jan 6;10(1):81. doi: 10.3390/vaccines10010081.
6
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa.南非 SARS-CoV-2 奥密克戎变异株的快速流行扩张。
Nature. 2022 Mar;603(7902):679-686. doi: 10.1038/s41586-022-04411-y. Epub 2022 Jan 7.
7
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
8
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.奥密克戎新冠病毒变体:新冠疫情的新篇章。
Lancet. 2021 Dec 11;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6. Epub 2021 Dec 3.
9
Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan.模拟日本不同疫苗接种率情景下的未来 COVID-19 疫情。
J Glob Health. 2021 Nov 30;11:05025. doi: 10.7189/jogh.11.05025. eCollection 2021.
10
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.免疫实践咨询委员会关于在 5-11 岁儿童中使用辉瑞-生物技术公司 COVID-19 疫苗的临时建议-美国,2021 年 11 月。
MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-1583. doi: 10.15585/mmwr.mm7045e1.